Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease

European Journal of Radiology

Volumn 76, Issue 1, 2010, Pages 129-134

  Heinz Peer, Gertraud ^a   Neruda, Anita ^a   Watschinger, Bruno ^a   Vychytil, Andreas ^a   Geusau, Alexandra ^a   Haumer, Markus ^a   Weber, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Dialysis patients; Endstage renal disease; Gadolinium based contrast agents; Nephrogenic systemic fibrosis; Prevalence

Indexed keywords

COFACTORS; DATA SUPPORT; END STAGE RENAL DISEASE; HIGH-RISK PATIENTS; INTRAVENOUS ADMINISTRATION; NEPHROGENIC SYSTEMIC FIBROSIS; PATIENT POPULATION; PERITONEAL DIALYSIS; PREVALENCE; PREVALENCE RATES; RENAL CLEARANCE; RISK FACTORS; SKIN BIOPSIES;

BIOPSY; BODY FLUIDS; CONTRAST MEDIA; DISEASES; GADOLINIUM; RADIOLOGY;

DIALYSIS;

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOXETIC ACID;

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; FATALITY; FEMALE; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; NEPHROGENIC SYSTEMIC FIBROSIS; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; PUVA; RETROSPECTIVE STUDY; RISK FACTOR; SKIN BIOPSY; SURGICAL PATIENT; THROMBOSIS;

AGED; BIOPSY; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PREVALENCE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 77957591881     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.06.028     Document Type: Article

References (39)

1. S.E. Cowper, H.S. Robin, S.M. Steinberg, L.D. Su, S. Gupta, and P.E. Leboit Scleromyxoedema-like cutaneous disease in renal-dialysis patients Lancet 356 2000 1000 1001
2. S.E. Cowper, L. Su, H. Robin, J. Bhawan, and P.E. LeBoit Nephrogenic fibrosing dermopathy Am J Dermatopathol 23 2001 383 393
3. S.E. Cowper, and P.J. Boyer Nephrogenic systemic fibrosis: an update Curr Rheumatol Rep 8 2006 151 157
4. S.E. Cowper Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy Am J Kidney Dis 46 2005 763 765
5. T. Grobner Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 2006 1104 1108
6. P. Marckmann, L. Skov, and K. Rossen Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging J Am Soc Nephrol 17 2006 2359 2362
7. H.S. Thomsen, S.K. Morcos, and P. Dawson Is there a causal relationship between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 61 2006 905 906
8. J.G. Penfield, and R.F. Reilly Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 21 2 2008 129 134
9. S.K. Morcos Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80 2007 73 76
10. Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF Web site] 2001-2007. Available at http://www.icnfdr.org, accessed October 30, 2007.
11. D.R. Broome, M.S. Girguis, P.W. Baron, A.C. Cottrell, I. Kjellin, and G.A. Kirk Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned AJR Am J Roentgenol 188 2007 586 592
12. M.A. Perazella Tissue deposition of gadolinium and development of NSF: a convergence of factors Semin Dial 21 2 2008 150 154
13. T.A. Collidge, P.C. Thomson, and P.B. Mark Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement cohort Radiology 245 2007 168 175
14. E.A. Sadowski, L.K. Bennet, and M.R. Chan Nephrogenic systemic fibrosis: risk factors and incidence estimation Radiology 243 2007 148 157
15. A. Deo, M. Fogel, and S.E. Cowper Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure Clin J Am Soc Nephrol 2 2007 264 267
16. C. Rydahl, H.S. Thomsen, and P. Marckmann High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent Invest Radiol 43 2008 141 144
17. H.S. Thomsen, Contrast media. Safety issues and ESUR guidelines vol. 17 2006 Springer-Verlag Berlin, Heidelberg 115 120
18. H.S. Thomsen Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide Eur Radiol 16 12 2006 2619 2621
19. M.R. Prince, H. Zhang, and M. Morris Incidence of nephrogenic systemic fibrosis at two large medical centers Radiology 248 2008 807 816
20. R. Wertman, E. Altun, and D.R. Martin Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities Radiology 248 2008 799 806
21. ®) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008;3(3):747-751.
22. F. January, J.M. Segal, J. Dyer, P. Leboit, E. Siegfried, and I.J. Frieden Nephrogenic fibrosing dermopathy: two pediatric cases J Pediatr 143 2003 678 681
23. S.M. Jain, S. Wesson, and A. Hassanein Nephrogenic fibrosing dermopathy in pediatric patients Pediatr Nephrol 19 2004 467 470
24. T.C. Lauenstein, K. Salman, and R. Morreira Nephrogenic systemic fibrosis: center case review J Magn Reson Imaging 26 2007 1198 1203
25. W.M. Shabana, R.H. Cohan, and J.H. Ellis Nephrogenic systemic fibrosis: a report of 29 cases AJR 190 2008 736 741
26. J.M. Ide, M. Port, and M. Schaefer Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review Fundam Clin Pharmacol 20 2006 563 576
27. P. Dawson Gadolinium chelates: chemistry P. Dawson, D.O. Cosgrove, R.G. Grainger, Textbook of contrast media 1999 Isis Medical Media Oxford 291 296
28. J.F. Desreux, and D. Gilsoul Chemical synthesis of paramagnetic complexes H.S. Thomsen, R.N. Muller, Mattrey Trends in contrast media 1999 Springer Verlag Heidelberg 161 169
29. I.M. Wahba, E.L. Simpson, and K. White Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature Am J Transplant 7 2007 1 8
30. Bayer Healthcare Pharmaceuticals: Magnevist contrast agent. Available at http://www.imaging.bayerhealthcare.com/html/magnevist/index.html, accessed February 19, 2009.
31. Omniscan: GE Healthcare. Omniscan Overview. Available at http://www.amershamhealthcare-us.com/omniscan/, accessed February 19, 2009.
32. European Medicines Agency: EPARs for Authorised Medicinal Products for Human Use. Available at http://www.emea.europa.eu/humandocs/Humans/EPAR/ optimark/optimark.htm, February 19, 2009.
33. T. Grobner Reply of letter to the editor Nephrol Dial Transplant 21 2006 3604 3605
34. P.E. LeBoit What nephrogenic fibrosing dermopathy might be Arch Dermatol 139 2003 928 930
35. M. Maloo, P. Abt, and R. Kashvap Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update Am J Transplant 6 2006 2212 2217
36. P. Joffe, H.S. Thomsen, and M. Meusel Pharmakokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis Acta Radiol 5 1998 491 502
37. T. Saitoh, K. Hayasaka, Y. Tanaka, T. Kuno, and Y. Nagura Dialyzability of gadodiamide in hemodialysis patients Radiat Med 24 2006 445 451
38. S. Okada, K. Katagirir, T. Kumazaki, and H. Yokoyama Safety of gadolinium contrast agent in hemodialysis patients Acta Radiol 42 2001 339 341
39. A. Abu-Alfa The impact of NSF on the care of patients with kidney disease J Am Coll Radiol 5 1 2008 45 52